Physician profile
Yifeng Chen
NPI 1447518535
$8,821.28
in general payments reported to CMS, 2019-2025
29 companies · $3,201 in 2025
The $3,201 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $103 · 2021: $270 · 2022: $995 · 2023: $1,089 · 2024: $2,679 · 2025: $3,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,672 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,671.92 |
| Education | $297.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,032.09 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $1,565.52 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $780.36 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $727.51 | 2022-2025 | Nucala |
| Optinose US, INC. | $558.74 | 2019-2025 | |
| Csl Behring | $448.74 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $447.97 | 2024-2025 | Takhzyro, Cuvitru, Hyqvia |
| Amgen INC. | $290.62 | 2022-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $281.97 | 2022-2025 | |
| Biocryst US Sales Co., LLC | $270.47 | 2022-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $269.25 | 2025 | Dawnzera |
| Genentech USA, INC. | $148.64 | 2024-2025 | Xolair |
| Kaleo, INC. | $130.94 | 2022-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $126.47 | 2022-2025 | |
| Pfizer INC. | $107.17 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $84.07 | 2025 | Ohtuvayre |
| Alk-Abello, INC | $76.80 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $67.07 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $58.32 | 2021-2023 | Verquvo |
| Pharming Healthcare, INC. | $48.87 | 2025 | Ruconest |
| Cycle Pharmaceuticals INC | $47.19 | 2025 | Sajazir |
| Medtronic, INC. | $45.33 | 2023-2024 | Sinuva |
| Phadia US INC. | $44.23 | 2024-2025 | Immunocap |
| Galderma Laboratories, L.P. | $41.29 | 2025 | Nemluvio |
| Hikma Pharmaceuticals USA | $29.36 | 2022-2024 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $26.80 | 2025 | Xhance |
| Grifols USA, LLC | $24.81 | 2025 | Xembify |
| Eyevance Pharmaceuticals LLC | $20.89 | 2020 | |
| Circassia INC. | $19.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yifeng Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.